Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.


Journal Article

A novel secreted glycoprotein that regulates bone resorption has been identified. The protein, termed Osteoprotegerin (OPG), is a novel member of the TNF receptor superfamily. In vivo, hepatic expression of OPG in transgenic mice results in a profound yet nonlethal osteopetrosis, coincident with a decrease in later stages of osteoclast differentiation. These same effects are observed upon administration of recombinant OPG into normal mice. In vitro, osteoclast differentiation from precursor cells is blocked in a dose-dependent manner by recombinant OPG. Furthermore, OPG blocks ovariectomy-associated bone loss in rats. These data show that OPG can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity.

Full Text

Cited Authors

  • Simonet, WS; Lacey, DL; Dunstan, CR; Kelley, M; Chang, MS; Lüthy, R; Nguyen, HQ; Wooden, S; Bennett, L; Boone, T; Shimamoto, G; DeRose, M; Elliott, R; Colombero, A; Tan, HL; Trail, G; Sullivan, J; Davy, E; Bucay, N; Renshaw-Gegg, L; Hughes, TM; Hill, D; Pattison, W; Campbell, P; Sander, S; Van, G; Tarpley, J; Derby, P; Lee, R; Boyle, WJ

Published Date

  • April 1997

Published In

Volume / Issue

  • 89 / 2

Start / End Page

  • 309 - 319

PubMed ID

  • 9108485

Pubmed Central ID

  • 9108485

Electronic International Standard Serial Number (EISSN)

  • 1097-4172

International Standard Serial Number (ISSN)

  • 0092-8674

Digital Object Identifier (DOI)

  • 10.1016/s0092-8674(00)80209-3


  • eng